BC Platforms AG, a world leader in genomic data management and analytics, today announces that it has partnered with Medaffcon Oy, a company specialised in generating real world evidence for health-related decision making
Medaffcon provides medical, scientific and market access services to international pharmaceutical and biotechnology industries as well as healthcare operators. The partnership focuses on harmonising complex genomic and clinical data from multiple sources applying joint specialist knowledge and technological capabilities.
With more than 20 years of experience in working with genomics and information technology, BC platforms has built a global network of biobanks providing a safe and secure environment for biobanks and researchers to determine data availability and advance research.
Since its establishment in 2009, Medaffcon has been working as an expert organisation with a core competence in scientific and health economic expertise.
Medaffcon has also been pioneering industry-driven biobank research efforts, since the establishment of the first biobanks in Finland. Medaffcon is owned by the PHOENIX group, a large integrated European Healthcare provider ensuring that patients and the public have access to high-quality healthcare across the Europe.
Jaana Ahlamaa, Medical and Market Access Director at Medaffcon, commented on the partnership: “We are very excited to be partnering with BC Platforms and their world leading network of biobanks through their BCRQUEST service. The collaboration will expand our capabilities of accessing and combining different Finnish and international data sources to advance research.”
Tero Silvola, CEO of BC Platforms, said: “We are delighted to partner with Medaffcon, part of the PHOENIX group. Our goal is to combine our global platform to leverage Medaffcon´s extensive expertise in key markets in order to utilise real world evidence faster and more effectively.”